Achilles Therapeutics PLC (FRA:698)

€ 0.71 0 (0%) Market Cap: 30.32 Mil Enterprise Value: -69.29 Mil PE Ratio: 0 PB Ratio: 0.27 GF Score: 34/100

Achilles Therapeutics PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Apr 24, 2023
Achilles Therapeutics PLC at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Achilles Therapeutics PLC at Eqt Life Sciences BioCapital Europe Transcript
Mar 09, 2023
Achilles Therapeutics PLC at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Achilles Therapeutics PLC ESMO IO Webcast Call Transcript
Dec 06, 2022
Achilles Therapeutics PLC at Bank of America Healthcare Conference Transcript
May 11, 2022
Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat Transcript
Apr 14, 2022
Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Achilles Therapeutics PLC SITC and Corporate Update Call Transcript
Nov 12, 2021

Achilles Therapeutics PLC ESMO IO Webcast Call Transcript

Dec 06, 2022 / 01:00PM GMT

Release Date Price: €1.57 (-1.26%)

Transcript

Operator

Welcome to the Achilles Therapeutics ESMO IO Interim Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session.

As a reminder, this call is being recorded today, Tuesday, December 6th, 2022.

I would now turn the call over to Lee Stern, Vice President, Investor Relations at Achilles. Lee, you may begin.

Lee Stern

Achilles Therapeutics - VP, IR and External Communications

Thank you. Hello everyone, and welcome to the Achilles Therapeutics ESMO IO Interim Update Conference Call.

Joining me today on today's call are Dr. Iraj Ali, our Chief Executive Officer; Dr. Karl Peggs, our Chief Medical Officer; and Dr. Sergio Quezada, our Chief Scientific Officer. After our formal remarks, we will conduct a question-and-answer session.

Earlier today, Achilles issued a press release announcing updated income results from the ongoing phase I/IIa CHIRON and THETIS clinical trials that were presented as part of a poster session

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.